paxil paroxetine
Click on image below to visit paxil Online Page
Apotex received tentative FDA approval of its abbreviated new drug application to market paroxetine hydrochloride tablets, the generic equivalent of GlaxoSmithKline’s antidepressant Paxil (paroxetine), which boasted sales of $1.8 billion in the United States last year. However, the approval is subject to 30-month stay periods due to outstanding litigation by GlaxoSmithKline in the U.S. District Court.
Advertisement
The litigation concerns patents that were issued by the Patent and Trademark Office and listed in the FDA’s Orange Book after Apotex had applied for FDA approval to market its generic Paxil. Apotex maintains these patents do not comply with statutory requirements for listing in the Orange Book and are an abuse of the regulatory system.
SmithKline Beecham (NYSE: SBH) announced today that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Paxil(R) (paroxetine HCl). The company is seeking marketing approval of Paxil for the treatment of posttraumatic stress disorder (PTSD), a condition that develops as a result of exposure to a traumatic event followed by reexperiencing the event, avoidance and hyperarousal. Traumas may include experiencing or witnessinPaxil without prescription
Paxel
Buy-paxil-online-no-prescription
Online pharmacy paxil paxil
Canadian online pharmacy paxil
Buy paxil online paxil
paxil prescriptions